Clinical trial
BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland
NCT07930715 is registered in ClinicalTrials.gov with University College Dublin as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- BRIGHT (Breast Cancer Resilience Intervention for Growth, Hope and Thriving): Co-Designing and Feasibility Testing a Culturally Tailored Resilience Intervention for Underserved Breast Cancer Survivors in Ireland
- Lead sponsor
- University College Dublin
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 31, 2029
- Completion date
- September 30, 2030
- Enrollment
- 80 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, cancer survivorship
Arms
As registered; 2 arms.
-
BRIGHT Resilience Intervention
Participants attend the 8-week culturally tailored BRIGHT resilience intervention: weekly 90-minute
-
Enhanced Usual Care
Participants receive standard oncology survivorship care plus the BRIGHT Survivorship Resource Booklet. They are offered the BRIGHT resilience intervention after the 3-month follow-up (waitlist crossover).
Primary endpoints
Registered primary outcome measures; 5 primary.
-
Recruitment Rate
Number of participants randomised per site per month. Progression target: at least 4 participants per site per month.
-
Retention
Percentage of randomised participants who complete the 3-month follow-up questionnaires. Progression target: at least 80%.
-
Session Attendance
Percentage of the 8 intervention sessions attended by participants in the BRIGHT arm, from attendance records. Progression target: at least 75% session completion.
-
Intervention Fidelity
Percentage of planned session components delivered as intended, assessed using facilitator session checklists and independent review of a sample of recorded sessions. Progression target: at least 85%.
-
Acceptability
Participant satisfaction with the intervention, measured using a questionnaire based on the Theoretical Framework of Acceptability, and explored in interviews with 15 to 20 participants and facilitators.
Lead sponsor's other trials
University College Dublin, most recent start first.
+108 more trials See the organization page
Similar trials
Same condition (Breast Neoplasms) and phase, most recent start first.
+4,050 more trials See the condition page